Summary:
VieCure has partnered with Guardant Health to integrate Guardant’s precision oncology tests into the AI-powered Halo Intelligence platform, enhancing access to genomic testing and decision support for community oncology practices.
Takeaways:
- Integrated Testing: Clinicians using VieCure’s platform can now order and receive Guardant’s genomic tests directly within their clinical workflow, eliminating manual processes.
- Enhanced Decision-Making: The Halo Intelligence platform supports real-time, evidence-based decisions by combining structured data, real-world evidence, and personalized care algorithms.
- Expanded Access: The partnership aims to democratize precision oncology by bringing advanced diagnostic tools to community practices nationwide.
VieCure Inc., pioneer of an intelligent cancer care ecosystem that democratizes precision oncology for community-based practices, today announced a strategic partnership with Guardant Health to embed Guardant’s next-generation sequencing (NGS)-based precision oncology tests into the VieCure Halo Intelligence platform. The integration represents the latest expansion of VieCure’s AI-based, scalable, and accessible technology, embedding critical testing required for patient diagnosis and advanced treatment.
Precision Oncology Relies on Several Platforms
Through this collaboration, oncology practices using VieCure Halo Intelligence will be able to order and receive results for Guardant tests for therapy selection and recurrence monitoring—including Guardant360 Liquid, Guardant360 CDx, Guardant360 Tissue, and Guardant Reveal—directly within their clinical workflow. Future phases will expand testing capabilities and enable deeper analytics within the platform. This integration eliminates manual processes and disconnected systems, giving clinicians timely, actionable insights at the point of care.
“We built the Halo Intelligence platform to be the most advanced, open operating system for oncology care,” says Michael Power, chief executive officer of VieCure. “Our mission has always been to make precision oncology practical for every provider, in every setting. This partnership with Guardant reinforces that vision by embedding powerful genomic diagnostics into everyday workflows.”
Halo Intelligence Platform Supports Real-time, Evidence-based Decisions
The Halo Intelligence platform combines structured clinical data, real-world evidence, and personalized care algorithms to support oncologists in making real-time, evidence-based decisions faster. With Guardant’s tests fully integrated, providers gain access to embedded molecular profiling workflows and enhanced clinical decision support, streamlining the path from biomarker discovery to therapeutic action.
“This partnership with VieCure will facilitate access to critical genomic testing for community oncology practices and streamline the ordering process for cancer care teams,” says Chris Freeman, chief commercial officer at Guardant Health. “Integrating Guardant tests into the Halo Intelligence platform will help ensure that more patients, regardless of where they receive care, can access the diagnostic tools needed to guide timely, personalized treatment.”
Guardant’s precision oncology tests are now available to the hundreds of providers who rely on the Halo Intelligence platform for real-time oncology insights nationwide. This collaboration marks another step in building an interoperable system that unites diagnostics, clinical data, and therapeutics into one intelligent care experience.
Featured Image: Viewimage | Dreamstime.com
